HER2-low
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
HER2-low
Jun 25, 2024, 16:01 |
Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X: . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
May 31, 2024, 10:41 |
Blog
Jason A. Mouabbi: Here are my anticipated Top 3 breast cancer presentations for ASCO24
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared a post on X:…
May 3, 2024, 16:17 |
Blog
Paolo Tarantino: HER2-low: should we even test?
Paolo Tarantino shared a post on X: "The timing couldn’t be more appropriate for this…
Apr 29, 2024, 15:54 |
Insight
Toni Choueiri: Big news to start the day: DESTINY-Breast06 Phase III trial
Toni Choueiri shared on X: "Big news to start the day: DESTINY-Breast06 Phase III trial…
All:
4
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube